ABAlexandra Balbir-Gurman

Alexandra Balbir-Gurman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandra Balbir-Gurman has a total of 149 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Initial Treatment Strategies and Outcomes Across Hemodynamic Thresholds and Risk Stratification in Incident Systemic Sclerosis–Associated Pulmonary Arterial Hypertension: A EUSTAR Analysis

    by Hilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, Cathrine Brunborg, Patricia E. Carreira, Paolo Airò, Carmen Pilar Simeón‐Aznar, Marie‐Elise Truchetet, Alessandro Giollo, Alexandra Balbir‐Gurman, et al.

    Objective: Real‐world initial treatment strategies in systemic sclerosis–associated pulmonary arterial hypertension (SSc‐PAH) remain incompletely described. We aimed to characterize these strategies across hemodynamic thresholds and risk strata and evaluate outcome associations. Methods: We analyzed treatment‐naive patients with SSc‐PAH from the European Scleroderma Trials and Research (EUSTAR) database (2000–2021) who fulfilled the 2022 hemodynamic definition. Initial therapy comprised treatment initiated within four months of right heart catheterization. As‐treated (AT) analyses were primary and intention‐to‐treat (ITT) analyses supportive. Outcomes were all‐cause mortality and 36‐month PAH progression. Results: Among 301 patients, 198 (66%) initiated therapy and 170 maintained therapy for at least three months. Therapy was initiated in 31% with milder hemodynamic impairment (mean pulmonary arterial pressure 21–24 mm Hg and/or pulmonary vascular resistance 2–3 Wood units) versus 79% fulfilling the previous hemodynamic definition; combination therapy increased from 14% to 67% across low‐ to high‐risk strata. Over a median 3.9 years, 125 patients (42%) died and 85 of 227 (37%) progressed. Adjusted ITT analyses showed no association with either outcome, whereas adjusted AT analyses showed lower mortality risk with sustained monotherapy and combination therapy (hazard ratio [HR] 0.50, 95% confidence interval [CI] 0.27–0.92, and HR 0.40, 95% CI 0.18–0.88, respectively) and lower PAH progression risk with sustained initial therapy (HR 0.37, 95% CI 0.18–0.76). In the milder hemodynamic subgroup, the mortality estimate was directionally consistent but imprecise. Conclusion: Initial treatment strategies reflected hemodynamic severity and baseline risk, whereas variation suggested potential implementation gaps. Sustained initial therapy was associated with lower risks of mortality and PAH progression. Contrasting ITT and AT estimates highlight challenges in observational treatment–outcome comparisons. Findings in the milder hemodynamic subgroup support dedicated prospective studies. image

  • The Natural History of Deficiency of Adenosine Deaminase 2 Vasculitis in a Large Cohort and Factors Associated With Disease-Related Damage

    by Dynne-Noya Kind Engelstein, David Levartovsky, Isaiah D. Wexler, Paulina Navon Elkan, Shai Padeh, Amir Bieber, Philip J. Hashkes, Liora Harel, Eduard Ling, Ofra Goldzweig, et al.

    Objective: To describe the clinical and laboratory findings, disease course, and treatment effectiveness of a large, genetically homogenous group of patients with deficiency of adenosine deaminase 2 (DADA2), and to identify factors associated with disease-related damage. Methods: We conducted a retrospective cohort study that included 45 patients with DADA2 vasculitis with long-term follow-up. Information was collected from patients’ charts, including demographic information, clinical presentations, laboratory findings, and treatment. The extent of disease-related damage was determined based on the Vasculitis Damage Index. Results: In this large homogenous cohort, we found that a young age at disease onset and periodic illness that included recurrent episodes of fever, myalgia, and abdominal pain were associated with disease-related damage. Patients with severe DADA2 disease responded favorably to tumor necrosis factor inhibitors (TNFi). Conclusion: Early age of onset and the periodic nature of the disease warrant prompt initiation of TNFi treatment to prevent later complications and severe disease progression.

  • Top Cited Papers
    Open Access

    Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort

    by Andrea‐Hermina Györfi, Tim Filla, Amin Polzin, Koray Tascilar, Maya Buch, Monique Tröbs, Alexandru‐Emil Matei, Paolo Airo, Alexandra Balbir‐Gurman, Frederic Kuwert, et al.

    Background: Systemic sclerosis (SSc) primary heart involvement (SSc‐pHI) is one of the leading causes of mortality in SSc. We aimed to evaluate risk factors for SSc‐pHI and its progression and the outcomes in the EUSTAR (European Scleroderma Trials and Research) cohort. Methods: SSc‐pHI was defined according to the World Scleroderma Foundation/Heart Failure Association definition. Data from 5741 patients with SSc in the EUSTAR cohort were analyzed. Additional cardiovascular data were collected from a subcohort of 838 patients with SSc. Lasso regression was used for risk factor analyses. Kaplan–Meier estimator was used for survival analyses. Progression of SSc‐pHI was evaluated by a study definition developed by rheumatology and cardiology experts. Results: Risk factors for the presence of SSc‐pHI comprised skeletal muscle atrophy (odds ratio [OR], 2.00 [95% CI, 1.00–2.68]), age (OR, 1.91 [95% CI, 1.73–2.03]), male sex (OR, 1.77 [95% CI, 1.42–2.05]), swollen joints (OR, 1.70 [95% CI, 1.47–1.98]), skeletal muscle weakness (OR, 1.38 [95% CI, 1.00–1.85]), and tendon friction rubs (OR, 1.46 [95% CI, 1.00–1.77]) (n=3276). Telangiectasia (OR, 2.10 [95% CI, 1.38–2.72]), intestinal symptoms (OR, 1.70 [95% CI, 1.04–2.42]), age (OR, 1.47 [95% CI, 1.21–1.62]), and antitopoisomerase I antibodies (OR, 1.37 [95% CI, 1.00–1.77]) were associated with an increased risk for new onset of SSc‐pHI (n=1000). Survival rate was significantly lower in patients with SSc‐pHI than in those without ( P value <0.0001, n=3768). Patients with SSc‐pHI had a lower survival rate than patients with interstitial lung disease (n=3365). Swollen joints were associated with an increased risk of progressive SSc‐pHI (OR, 2.49 [95% CI, 1.79–3.52]) (n=595). Tendon friction rubs (OR, 1.21 [95% CI, 0.94–1.90]) increased the risk of heart failure with preserved ejection fraction in patients with SSc‐pHI. Conclusions: We defined progressive SSc‐pHI and identified risk factors for new onset and progression of SSc‐pHI and for SSc‐pHI‐associated heart failure with preserved ejection fraction in the largest cohort with SSc. These findings may guide patient stratification for diagnostic workup and therapy.


  • Open Access

    A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis

    by Hilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, Cathrine Brunborg, Patricia E Carreira, Paolo Airò, Carmen Pilar Simeón-Aznar, Marie-Elise Truchetet, Alessandro Giollo, Alexandra Balbir-Gurman, et al.

    Objectives: The 2022 European Society of Cardiology and European Respiratory Society (ESC/ERS) guidelines for pulmonary arterial hypertension (PAH) recommend risk stratification to optimize management. However, the performance of generic PAH risk stratification tools in patients with SSc-associated PAH remains unclear. Our objective was to identify the most accurate approach for risk stratification at SSc-PAH diagnosis. Methods: In this multicentre, international cohort study from the European Scleroderma Trials and Research (EUSTAR) group database, we screened 11 risk stratification tools upon SSc-PAH diagnosis. We compared the performance of the three top-ranked tools to predict mortality with the ESC/ERS three-strata model, the currently recommended tool for baseline risk assessment. We also assessed the impact of incorporating SSc-specific characteristics into the tools. Kaplan–Meier analyses and Cox regression with area under the ROC curve (AUC) were conducted. Results: The ESC/ERS three-strata model had a lower ability to predict mortality than the ESC/ERS four-strata model, ‘SPAHR updated’ and ‘REVEAL Lite 2’. The ESC/ERS four-strata model divided ‘intermediate-risk’ patients into two groups with significantly different long-term survival rates and is the easiest applicable tool. Incorporating SSc-specific characteristics did not significantly improve the predictive ability of any model, but a low diffusing capacity of the lung for carbon monoxide (DLCO) was an independent predictor of mortality. Conclusion: Considering its ability to predict mortality, risk segregation capabilities and clinical applicability, this study provides a rationale for using the simplified ESC/ERS four-strata model at SSc-PAH diagnosis as an alternative to the comprehensive ESC/ERS three-strata model. We propose considering DLCO as an individual prognostic marker in SSc-PAH.


  • Top Cited Papers

    LGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma

    by Chamutal Gur, Shuang-Yin Wang, Fadi Sheban, Mor Zada, Baoguo Li, Fadi Kharouf, Hagit Peleg, Suhail Aamar, Adam Yalin, Daniel Kirschenbaum, et al.


  • Open Access

    OP0013 SINGLE CELL PROFILE OF SKIN STROMAL AND IMMUNE CELLS AND PERIPHERAL BLOOD IMMUNE CELLS OF SCLERODERMA PATIENTS TOWARDS IDENTIFICATION OF DISEASE MECHANISM, PROGNOSTIC BIOMARKERS AND POTENTIAL THERAPEUTIC TARGETS

    by C. Gur, A. Balbir-Gurman, H. Peleg, S. Aamar, F. Kharouf, Y. Braun-Moscovici, S. Y. Wang, I. Amit

    Background: Despite many years of research, our understanding of Systemic Sclerosis (SSc) pathogenic processes, patient-to-patient variability, and diversity of stromal and immune cells within the involved tissues microenvironment, their interaction, as well as the genes and pathways leading to the pathogenesis remains largely unclear. Current technologies for characterizing SSc have limited depth and resolution, which needed for molecular define the small skin stromal and immune cells sub-populations supposed to drive SSc pathogenesis. Single-cell sequencing technologies hold a great potential in genomic medicine since they offer high resolution and sensitivity for unbiased profiling of disease versus normal niches. Objectives: Comprehensive characterization of stromal and immune cells in the skin and blood of SSc patients, and healthy controls, their specific intra-skin cell states, pathways, cell-cell interactions, and unbiased characterization of cell types profile, biomarkers, drivers, and regulatory pathways associated with specific SSc patient subgroups. Methods: We applied the massively parallel single cell RNA-seq (MARS-seq) developed in our laboratory to conduct a comprehensive single-cell genomics analysis of skin stromal and immune cells obtained through punch biopsy and blood immune cells from 73 SSc patients (39 DcSSc, 34 LcSSc) and 30 healthy controls. We used the MetaCell analytical method to identify homogeneous and robust groups of cells from single cell RNA-seq data. The perturbed signaling pathways, pathogenic stromal or immune cell subsets are characterized using CyTOF, immunohistochemistry, Physical Interacting Cell sequencing (PIC-seq), and in vitro functional assays. Results: We collected data from a total of 46,742 high-quality skin stromal cells, and 57,475 high-quality blood and skin immune cells. Analysis of stromal cell compartment led to a detailed map of 261 meta cells organized into 16 broad lineages including: Fibroblasts, Pericytes, Vascular cells, and other cells. In the immune cell compartment, we found 361 meta cells organized into 14 broad lineages (e.g unique skin T, B, NK and dendritic cells). We observed a unique population of stromal and immune cells in the skin and blood of SSc patients as compared to controls. The major and dramatic changes were observed in the stromal cell compartment of the patient’s skin compared to controls. In the fibroblast lineage we found a small cluster of cells that were significantly diminished in the SSc patients compared with control, expressed genes associated with fibrosis and vascular remodeling. Significantly higher number of specific subsets of pericytes and vascular cells was found in SSc patients compared to controls. Analysis of the immune cell compartment revealed only minor changes in the immune cell composition in patients compared with controls. Finally, we found known and novel pathways (e.g Wnt/Notch signaling, IFN type I/II, AP-1 pathway, complement cascade activation) and cell-cell interactions that play crucial roles in SSc pathogenicity. Conclusion: Our study provides a detailed and unprecedented high-resolution atlas of the immune and stromal cells that make up the skin and peripheral blood in a large cohort of SSc patients with diverse disease duration and clinical settings. Our findings of candidate stromal and immune cell subpopulation, genes and pathways constitute the basis for understanding of SSc pathogenesis and heterogeneity and holds great potential to provide clinicians with new and powerful molecular tools for understanding of the immune-stromal cell crosstalk, for finding new biomarkers for SSc activity and complications and for tailoring and identification of new therapeutic targets. Disclosure of Interests: Chamutal Gur: None declared, Alexandra Balbir-Gurman Consultant of: Novartis, Hagit Peleg: None declared, Suhail Aamar: None declared, Fadi Kharouf: None declared, Yolanda Braun-Moscovici: None declared, Shuang-Yin Wang: None declared, Ido Amit: None declared

  • Open Access

    Treat-to-target concept implementation for evaluating rheumatoid arthritis patients in daily practice

    by Tal Gazitt, Shirley Oren, Tatiana Reitblat, Merav Lidar, Alexandra Balbir Gurman, Itzhak Rosner, Nimer Halabe, Joy Feld, Sameer Kassem, Idit Lavi, et al.

    Objective: We aimed to assess the implementation of the treat-to-target (T2T) concept in rheumatoid arthritis (RA) patients in daily practice. Methods: All RA patients visiting one of the 7 academic medical centers in Israel in June 2015 with at least 3 previous clinic visits were included in this study. A common questionnaire was used to collect data from patients’ medical records, and two independent rheumatologists evaluated the collected data for the implementation of the T2T concept. The associations between T2T implementation and the categorical and continuous variables were assessed. Results: The study included 724 patients with a mean (standard deviation) age of 62.6 (13.97) years and 575 (80.4%) of them were women. Four centers used more than one scoring method, with Disease Activity Score-28 and Clinical Disease Activity Index) being most commonly used. Only 276 (38.1%) patients had disease score results in ≥3 visits, and the T2T recommendations were implemented for 245 (33.8%) of the 724 patients. The rate of implementation was higher in younger (p=0.028) rheumatoid factor-positive patients (p=0.011) and varied between centers (11.1%-87% p


  • Open Access

    Diffuse Large B Cell Lymphoma Mimicking Granulomatosis with Polyangiitis

    by Mohammad E. Naffaa, Alexander P. Rozin, Netanel Horowitz, Ofer Ben-Itzhak, Yolanda Braun-Moscovici, Alexandra Balbir-Gurman

    In a patient with systemic multiorgan disease with overlapping features, the differential diagnosis included infectious diseases, malignancies, and systemic autoimmune or inflammatory diseases. We present an unusual case of a young male with B cell lymphoma who presented with symptoms mimicking systemic vasculitis and review the existing literature.


  • SAT0213 Hypocomplementemia During Tocilizumab Treatment for Rheumatoid Arthritis:Long Term Follow-Up Results

    by Y. Braun-Moscovici, M. Braun, D. Markovits, A. Balbir-Gurman

    Background Hypocomplementemia was previously reported in patients (pts) with rheumatoid arthritis (RA) treated with tocilizumab (TCZ). Decreased complement (C3,C4) production was suggested as a possible mechanism. The long-term consequences concerning serious bacterial infections or autoimmune disorders (AID) have not been reported. Objectives To assess the long-term outcome of RA pts treated with TCZ who developed hypocomplementemia regarding serious bacterial infections or AID. Methods The charts of RA pts treated with TCZ at our center were reviewed retrospectively. Data regarding pts' age, gender, disease duration, presence of rheumatoid factor (RF), antibodies to citrullinated peptide (ACPA), and nuclear antigens (ANA), previous and concomitant non-biological DMARDs, previous biological DMARDs, and TCZ treatment duration; laboratory parameters including leucocytes and thrombocytes count, liver enzymes, C3 and C4 levels at baseline and during TCZ treatment; episodes of infections, allergic reactions, and AID were captured and analyzed. Results Thirty five pts out of 85 RA pts treated with TCZ, at our center, had serial measurements of serum complement concentration. Fourteen pts (mean age 58.3 years, mean disease duration 8.6 years) developed low C4 levels (9 had also low C3). Mean TCZ treatment period was 4.6 years (range 1-10 years). All patients had normal complement levels at baseline. Seven pts developed persistent leukopenia, 3 pts had persistent thrombocytopenia, 3 pts developed liver enzymes elevation. No serious bacterial infections or new onset AID occurred during follow up. One patient developed a severe allergic reaction. Persistent leukopenia was observed only in 2 out of 21 pts with normal complement levels, as opposed to 5 out of 14 pts with hypocomplementemia. No patients with normal complement levels developed thrombocytopenia. No significant differences regarding previous biologic or concomitant DMARD's treatment were found between the 2 groups of pts. Conclusions Long-term follow up of RA pts treated with TCZ who developed hypocomplementemia did not reveal an increased rate of serious bacterial infections or AID. Persistent leukopenia and thrombocytopenia were frequent in these pts; the relationship to hypocomplementemia needs to be further elucidated. Disclosure of Interest None declared